alpha-1A adrenergic receptor Agonists
1 drugsAbout alpha-1A adrenergic receptor
The alpha 1A adrenergic receptor (α1A-AR) is a G protein-coupled receptor activated by catecholamines like norepinephrine and epinephrine. It mediates smooth muscle contraction and plays a role in various physiological processes.
The α1A-AR is a drug target, but there is currently no genetic evidence directly linking it to specific diseases. Its role in smooth muscle contraction makes it a valuable target for pharmacological intervention.
Two FDA-approved drugs target the α1A-AR: tamsulosin hydrochloride and silodosin. Both drugs are small molecules and are classified within the 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Lower Urinary Tract Symptoms with only 1 trials.
Top alpha-1A adrenergic receptor Drugs
Novartis and PRINSTON INC are the companies with approved drugs targeting alpha 1A adrenergic receptor.
The market is concentrated, so new entrants need a strong value proposition to compete.
alpha-1A adrenergic receptor Clinical Trials 24 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 4 | 4 | 0 | 0 | 100% |
| Phase 3 | 5 | 2 | 2 | 1 | 50% |
| Phase 4 | 13 | 8 | 1 | 4 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (8 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 11 clinical trials targeting alpha-1A adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities